Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Veracyte, Inc. (NASDAQ:VCYT) by **12.5%**, acquiring an additional **22,074 shares**, bringing its total ownership to **198,592 shares** valued at approximately **$5.89 million**.
• Several hedge funds, including **Vanguard Group** and **ArrowMark Colorado Holdings**, also raised their stakes in Veracyte, indicating growing institutional interest in the company.
• Analysts have mixed opinions on Veracyte's stock, with **nine "buy" ratings**, but recent price targets suggest a decline, reflecting a **moderate buy** rating as the average target price stands at **$40.90**.

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 12.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 198,592 shares of the biotechnology company's stock after purchasing an additional 22,074 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.25% of Veracyte worth $5,888,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of VCYT. Allspring Global Investments Holdings LLC boosted its position in shares of Veracyte by 54.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 13,538 shares of the biotechnology company's stock valued at $400,000 after purchasing an additional 4,792 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Veracyte by 122.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 18,199 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 10,022 shares during the period. Bank of New York Mellon Corp increased its position in Veracyte by 2.0% during the first quarter. Bank of New York Mellon Corp now owns 248,224 shares of the biotechnology company's stock worth $7,360,000 after acquiring an additional 4,772 shares during the period. Principal Financial Group Inc. increased its position in Veracyte by 9.5% during the first quarter. Principal Financial Group Inc. now owns 35,663 shares of the biotechnology company's stock worth $1,057,000 after acquiring an additional 3,103 shares during the period. Finally, Bayesian Capital Management LP acquired a new stake in Veracyte during the fourth quarter worth $693,000.

Analyst Ratings Changes

Several equities research analysts have recently commented on VCYT shares. Needham & Company LLC reduced their target price on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. UBS Group cut their price objective on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded Veracyte from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Guggenheim decreased their price target on Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.90.

Veracyte Stock Down 0.9%

NASDAQ:VCYT traded down $0.23 during trading hours on Monday, reaching $25.02. 15,568,823 shares of the stock were exchanged, compared to its average volume of 1,061,774. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 61.03 and a beta of 2.07. Veracyte, Inc. has a twelve month low of $19.73 and a twelve month high of $47.32. The business has a 50-day moving average of $26.62 and a two-hundred day moving average of $32.08.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.